A single protein that appears necessary for the COVID-19 virus to reproduce and spread to other cells is a potential weakness that could be targeted by future therapies.
Jenna Scott was 29, seven months pregnant, and suddenly, feeling very sick.
Studies reveal potential weaknesses in SARS-CoV-2 infection
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Maura L. Gillison, MD, PhD, a medical oncologist and molecular epidemiologist whose work changed the standard of care for head and neck cancer by distinguishing human papillomavirus-positive from HPV-negative disease and thereby guiding diagnosis, treatment and prevention, died on June 21.
I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
The American Association for Cancer Research is urging the White House Office of Management and Budget to rescind its recent proposed rule that would give the administration unprecedented political control over government-funded science.
The Centers for Disease Control and Prevention has published an updated version of the charter for the Advisory Committee on Immunization Practices.
